Conference Agenda

Interactive and Thought provoking conference sessions

Home Agenda
Event Schedule - 2026

Our Events Schedule Plan

Registration & Refreshments

Kick off your conference experience by checking in at our registration desk. Collect your event materials and enjoy a selection of refreshments. It's the perfect time to mingle with fellow attendees and set the tone for an engaging and informative event


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Welcome Address & Chairperson’s Opening Remarks

Begin your conference journey with a warm welcome from our esteemed Chairperson

Konrad Dobschuetz

Founder Director

Leap Advisory & Intelligence

Enabling DMTA-Agents in Drug Discovery

What decisions in the DMTA-process do we want an Agent to support us with? What information would the Agent need to trigger actions and give useful advice? This presentation will give an overview of three key types of information an Agent would need, and the systems we are building internally at AstraZeneca to gather this information.

Jenny Viklund

Principal Scientist Computational Chemistry

AstraZeneca


Innovation in Drug Discovery
Drug Discovery and Development
Beyond the Hype: Practical GenAI in Drug Design

Danny Asher Bitton

Director, Applied Research and Innovation

MSD Czech Republic


Innovation in Drug Discovery
AI-Driven Innovation
Accelerating Drug Discovery with AI: Breakthroughs, Challenges, and the Road Ahead

Remco Loos

Former Bristol Myers Squibb, Senior Director - Applied AI


AI-Driven Innovation
Drug Discovery and Development
Business Card Exchange with Morning Coffee/Tea & Discussion

Network over morning coffee or tea, exchanging business cards or using our app's QR code scanner for easy contact sharing. A prime moment for engaging discussions and new connections


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Predictive Science and Agentic AI Developments for Chemical Development

Christof Jaeger

Senior Director, Predictive Science, Digital & Automation, Pharmaceutical Sciences

AstraZeneca


AI and ML in Pharma
Sustainability
AI Pilots Work. So Why Don't They Scale?

AI pilots work. Scaling them doesn't. Once AI enters real workflows, companies face a different challenge: governing access, securing knowledge, controlling costs, and making AI usable across the organization. This talk explores what breaks when AI moves from isolated pilots into enterprise operations, and what companies need to build between "the pilot works" and "this runs in production": the operating layer around AI. Drawing from hands-on implementation experience, we'll look at governance, context management, security, cost control, and why the biggest bottleneck to scaling AI isn't the model. It's the organization.

Michael Muehlberger

Founder & CEO

SPACE44

Luncheon & Networking - Explore, Engage with Your Peers and Connect at Our Exhibitor Booths

Enjoy a luncheon while networking with peers and exploring exhibitor booths. This is an ideal time to engage with industry leaders, delve into innovative solutions, and forge valuable connections in a collaborative atmosphere.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Building Agentic AI Systems Inside a regulated environment

Jordi Escayola

Global Head Advanced Analytics, Artificial Intelligence & Data Science

Opella


Digital Transformation
AI-Driven Innovation
Digital, Data, and AI: Transform to Scale in Pharma R&D

What does it take to scale digital, data, and AI in pharma R&D? Why do some organizations seem to be more successful in adopting new technology such as AI on a broad scale, while others struggle? Using examples from the Development space, this talk will make the case that even in the age of AI, strong data foundations are a non-negotiable factor in enabling complex, cross-functional business challenges and processes.

Markus Heckenmuller

Principal

Vertwo Advisory

Federated Learning and (Gen) AI are Transforming how we Treat, Learn and Innovate in Healthcare
  • Building data ecosystems to scale collaborative research and RWE generation
  • Leveraging GenAI to enhance data quality and density
  • Learning from every patient we treat

Frederik Buijs

Senior Medical Director

Roche

Benchmarking the Impact of AI in Biologics Discovery and Optimization for Pharma

The biologics landscape is undergoing rapid transformation as AI-enabled candidates progress through preclinical and clinical development. This shift is fuelled by enterprise-scale data capture and management, increasingly automated discovery workflows, advances in machine learning, and expanding computational capacity. Augmented biologics discovery has the potential to reshape how biologics are designed, engineered, and optimized. This presentation describes the current state of in silico biologics design and optimization technologies and focusses on internal benchmarking of their impact when combined with established biologics discovery platforms.

Olga Obrezanova

AI Principal Scientist

AstraZeneca


Innovation in Drug Discovery
AI-Driven Innovation
Trust, Teach, Transform: Data Governance, Literacy & Sharing in the Age of AI

Frank Dullweber

Data Domain Owner - Data Governance & Insights in Clinical Development & Operations

Boehringer Ingelheim


Regulatory and Ethical Considerations
Leadership and Strategy
Recharge with Tea or Coffee While Networking

Refresh with a tea or coffee break, using this time to continue networking. It's a perfect opportunity to discuss ideas, share experiences, and connect with fellow attendees in a relaxed setting.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Panel Discussion: AI and Automation in Drug Discovery: From Hype to Real-World Breakthroughs – Can Innovation Keep Up with Regulation?
  • How close are we to AI-designed drugs reaching patients — and what’s still missing in validation and translation?
  • Are global frameworks agile enough to assess and approve discoveries driven by algorithms?
  • What real-world examples reveal the difference between AI hype and genuine productivity gains in discovery?
  • When AI suggests a molecule or pathway, who takes responsibility if it fails — the scientist, the system, or the sponsor?
  • How will AI, quantum computing, and automation converge to redefine timelines, talent, and trust in the pharma R&D ecosystem?

Regulatory and Ethical Considerations
AI-Driven Innovation

Konrad Dobschuetz

Founder Director

Leap Advisory & Intelligence

Olga Obrezanova

AI Principal Scientist

AstraZeneca

Frederik Buijs

Senior Medical Director

Roche

Esben Jannik Bjerrum

Principal Research Scientist II, AI / ML Team Lead

AbbVie

Mohammad Hassan Khalid

Head of AI/ML

Portal Biotech Ltd

Remco Loos

Former Bristol Myers Squibb, Senior Director - Applied AI

Automating Clinical Pharmacometric Model Development: From ML to Agentic AI

Sam Richardson

Associate Director, Machine Learning & AI

AstraZeneca


AI-Driven Innovation
Clinical Trials & Research Innovation
Regulatory science supporting standardisation in molecular diagnostics

MHRA is a world leader in the field of Regulatory science. Regulatory Science is a field of scientific research focused on developing the tools, standards, and approaches needed to generate the data on which Regulatory Agencies assesses the safety, efficacy, quality, and performance of regulated pharmaceuticals and medical devices products. Working together with partners, the Genomics team has delivered several Reference materials and to support public and private sectors and contributes to international initiatives to support the standardisation of the molecular diagnostic field.

Leandro Lo Cascio

Head of Genomics

Medicines and Healthcare products Regulatory Agency


Regulatory and Ethical Considerations
Innovation in Drug Discovery
Chairperson’s Closing Remark

End of Day 1 with the Chairperson's closing remarks and summarising key insights

Konrad Dobschuetz

Founder Director

Leap Advisory & Intelligence

Networking Drinks Session

Wrap up the day with evening drinks and lively conversations. A relaxed setting to network, share insights from the day, and enjoy the company of fellow attendees.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Registration & Refreshments

Start the second day of the conference by checking in and grabbing a morning refreshment. It’s a great opportunity to re-engage with peers, discuss the previous day’s insights, and prepare for another day of learning and networking.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Welcome Address & Chairperson’s Opening Remarks

Start the second day with insightful remarks from our Chairperson

Bruce Hellman

Co-Founder & Chief Patient Officer

uMotif

The Invisible Trial: Merging Research into the Workflow of Care

Karina Morley

Global Head Innovative Research & Strategic Alliances Biopharmaceutical Medical

AstraZeneca


AI-Driven Innovation
Clinical Trials & Research Innovation
Accelerating Translational R&D with Genomics

James Duboff

Strategic Partnerships Director

Genomics England


Drug Discovery and Development
Precision Medicine and Genomics
SMILES is All You Need - for Chemical Deep Learning in Drug Discovery

Esben Jannik Bjerrum

Principal Research Scientist II, AI / ML Team Lead

AbbVie

Business Card Exchange with Morning Coffee/Tea & Discussion

Network over morning coffee or tea, exchanging business cards or using our app's QR code scanner for easy contact sharing. A prime moment for engaging discussions and new connections.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Accelerating Lab-in-a-Loop with Self-Service MLOps

Le (Muller) Mu

MLOps lead, Computational Sciences Center of Excellence

Roche

Transparent Agentic AI for Evidence Discovery: Speed with Scientific Rigor

Tassnim Abdessalem

Data Scientist

AstraZeneca

Sanjay Rathee

Associate Director in Data Science & AI

AstraZeneca

Accelerating evidence-based decision making in R&D: Connecting Strategy, Portfolio, and Evidence Across the Lifecycle

Stijn Janssen

Digital Leader R&D Digital Transformation

Novo Nordisk


Innovation in Drug Discovery
Real-World Data (RWD) and Evidence (RWE)
Luncheon & Networking - Explore, Engage with Your Peers and Connect at Our Exhibitor Booths

Enjoy a luncheon while networking with peers and exploring exhibitor booths. This is an ideal time to engage with industry leaders, delve into innovative solutions, and forge valuable connections in a collaborative atmosphere.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Panel Discussion: Advancing Drug Discovery and Patient Care: The Synergy of Emerging Technologies in Pharma-Health Collaboration
  • Why is it important for pharma and healthcare to work together?
  • The changing patient behaviour in the digital era
  • Why is it essential to be prompt in identifying and addressing the patient’s needs?
  • How will digitization help bring patients on board?
  • Progress made by companies so far
  • Strategies to be adopted to increase patient –company data flow

Collaborative and Partnering Strategies
Patient Care and Drug Development

Bruce Hellman

Co-Founder & Chief Patient Officer

uMotif

James Duboff

Strategic Partnerships Director

Genomics England

Karla Viviani Allebrandt

Gl. Sr. Manager / Sr. Scientific Expert

Boehringer Ingelheim

Vicent Benet Gil

Data Strategy Lead

SDG Group

Murat Akturk

Global Sr. Director of Growth and Partnership/AI & Digital Innovation

GE HealthCare

Foundation Models for Real‑World Patient Data: Representation Learning at Scale for Pharma R&D

Johann De Jong

Data Science Lead

UCB


AI-Driven Innovation
Drug Discovery and Development
Laying the foundations for data‑ and AI‑driven drug discovery: from lab digitalisation to AI‑augmented scientists
  • Digitalise labs and data at the source to ensure quality, FAIR, and traceable data.
  • Build scalable data and AI foundations to support ML and scientific compute: some end-to-end use cases supporting drug discovery
  • Democratise AI for scientists and enable adoption at scale through accessible tools and sandboxes, supported by governance, training, and change management

Miriam Lopez Ramos

Head of Data and AI Products for Research & CMC

Servier


AI and ML in Pharma
Drug Discovery and Development
AI, Automation & LLM‑Powered Transformation: Concept to realization; High‑ROI Use Cases in Healthcare Sales and Service Optimization

Murat Akturk

Global Sr. Director of Growth and Partnership/AI & Digital Innovation

GE HealthCare


AI-Driven Innovation
Automation
Recharge with Tea or Coffee While Networking

Refresh with a tea or coffee break, using this time to continue networking. It's a perfect opportunity to discuss ideas, share experiences, and connect with fellow attendees in a relaxed setting.


Download our app now to connect with attendees, enhance your networking opportunities, and stay updated effortlessly!

Enhancing Clinical Trial Site Identification and Selection through Data Science and Predictive Analytics

Dafni Glinos

Principal Data Scientist

Vertex Pharmaceuticals


Data Science, Big Data & Informatics
Clinical Trials & Research Innovation
Strategic Foresight: Architecting High-ROI AI Use Cases in Real-World Evidence Generation
  • Moving from RWD Infrastructure to Evidence Engines: Shifting the organizational focus from building static data lakes to deploying dynamic, AI-driven platforms that accelerate regulatory and market access decisions.
  • Agentic AI vs. traditional GenAI: Applying goal-oriented, autonomous AI agents for complex RWE tasks (e.g., automated signal detection, regulatory interpretation, and multi-step reasoning) rather than relying on basic chatbots.
  • Governing the "Loop" for Regulatory Acceptance: Designing risk-adapted oversight frameworks to successfully handle GenAI's probabilistic behaviour in deterministic regulatory settings.
  • Federated Data as the AI Enabler: Overcoming data silos and privacy constraints by deploying AI models directly to global, decentralized real-world data networks.
  • Mitigating "Validation Debt": Embedding GxP compliance, immutable audit trails, and strict security guardrails into Agentic AI workflows to ensure the validity and trustworthiness of AI-generated evidence.

Alireza Moayyeri

Senior Director - RWE Global

UCB


AI-Driven Innovation
Real-World Data (RWD) and Evidence (RWE)
Digital Tools, Real Risk: Securing Patient Safety and Clinical Trials Processes at the Edge

Digital tools are transforming clinical trials, but they also introduce risks that extend far beyond IT. This session examines how emerging technologies, including AI, impact patient safety, data integrity, and sponsor liability. Participants will learn how to approach the procurement and use of AI with an ethical, risk-based mindset, evaluating systems not just for performance but for transparency, bias, and regulatory alignment. The session also reframes cybersecurity of devices as a patient safety issue, highlighting how vulnerabilities can affect trial outcomes and organizational risk. By linking smarter procurement with stronger safeguards, this session helps leaders navigate innovation without compromising trust or safety.

Maria Palombini

Global Director, Healthcare & Life Sciences Practice

IEEE Standards Association

Chairperson’s closing remarks & End of Conference

End the conference with the Chairperson's closing remarks, summarizing key insights and leaving attendees with final thoughts to inspire ongoing engagement and action.

Bruce Hellman

Co-Founder & Chief Patient Officer

uMotif